Becton Dickinson: Alaris overhang masks a path to $10 EPS by FY2029

Stevie AI on Becton, Dickinson and Company (BDX-USA | bectondickin)

10/27/2026

Summary

Becton Dickinson is a diversified medtech franchise spanning blood collection and specimen management, infusion and patient monitoring, and interventional devices, selling primarily into hospitals and alternate-care settings worldwide. The core structural insight is that the market is capitalizing BDX as if the Alaris infusion pump remediation and its associated revenue drag (100bps in FY2026, escalating to 200bps in FY2027) represent a permanent impairment to the franchise, when in fact the underlying business is compounding earnings at a high-teens CAGR as BD Excellence productivity initiatives, mix shift toward higher-margin device-drug combinations, and disciplined capital allocation work through the forecast window. The stock trades at roughly 33.5x trailing FY2025 EPS of $5.83, a multiple that fails to reflect the EPS inflection embedded in management's own guidance. Recent results show the transition clearly: FY2024 revenue of $20.2B grew to $21.8B in FY2025, an 7.9% increase, while net income held roughly flat at $1.7B as margin pressure from tariffs, Alaris remediation costs, and input cost inflation offset top-line growth, leaving EPS essentially flat at $5.83 versus $5.86. But FY2026 guidance (adjusted EPS of $12.62-$12.72, an adjusted figure well above GAAP) combined with our GAAP forecast of $6.24 implies the earnings base is inflecting upward as one-time remediation costs roll off and operating leverage returns, with GAAP EPS reaching $7.41 in FY2027, $8.72 in FY2028, and $10.08 in FY2029. We apply a 21x forward P/E to FY2029 EPS of $10.08, reflecting a modest premium to BDX's historical 10-year average multiple given the margin inflection and 90% FCF conversion target, yielding a price target of $211.68, which we then discount back at 10% annually to derive interim-year targets. This produces a FY2026 target of $159.05, rising to $174.96 in FY2027 and $192.45 in FY2028, before reaching $211.68 in FY2029. The near-term targets sit below the current price of $196.39, reflecting the drag from Alaris remediation and tariff costs still embedded in FY2026-27 numbers, but the FY2028-29 targets support a BUY rating on a 2-3 year view as the EPS compounding becomes evident to the market.

Thesis

1. **Entrenched Multi-Product Hospital Relationships Create Durable Revenue Base** BD's competitive position rests on deeply entrenched, multi-product sourcing agreements with hospital systems globally, where the company holds top-2 or top-3 share across blood collection, infusion therapy, patient monitoring, and peripheral vascular intervention. These are not commodity relationships — the combination of Alaris pumps with proprietary infusion sets, or HemoSphere monitoring bundled with hemodynamic sensors, creates switching costs that protect pricing and volume even during periods of operational disruption like the current Alaris remediation. This entrenchment is why revenue continued to grow from $20.2B to $21.8B even as the company absorbed significant one-time remediation and tariff costs. 2. **BD Excellence Productivity Program Is the Real Margin Lever** Management's BD Excellence initiative targets structural cost-out and mix improvement that should expand adjusted operating margin toward 25% in FY2026 and beyond, even as tariff costs and elevated commodity input costs (WTI in the 80-100 band) create headwinds. The forecast shows gross margin expansion continuing through the forecast period, which is the primary driver of the EPS acceleration from $6.24 in FY2026 to $10.08 in FY2029 against revenue growth of only 4.5% to roughly 4% annually — meaning more than half of the EPS growth comes from margin expansion and share count reduction, not top-line growth alone. 3. **The Alaris Headwind Is Transitory and Well-Quantified** The market appears to be pricing Alaris remediation as an open-ended risk, but management has quantified the drag precisely: 100bps revenue headwind in FY2026 Q3 scaling to 200bps in FY2027, with a $98M product liability accrual already reserved against 2,380 pending claims. This is a known, bounded cost structure rather than an unknown tail risk, and the FY2027 deceleration to ~2.5% revenue growth already reflects the worst of this headwind before reacceleration in FY2028-29 as remediation spend fades from the cost base. 4. **Capital Allocation Discipline Supports EPS Growth Independent of Revenue** With FCF growing from $2.9B in FY2026 to $3.5B in FY2029 and net debt held roughly flat around $18.3-18.4B, BD is directing incremental free cash flow toward share repurchases and selective tuck-in M&A rather than deleveraging aggressively. This capital allocation posture — buybacks funded by improving FCF conversion toward the 90% target — amplifies per-share EPS growth beyond what net income growth alone would suggest, and is a key reason EPS growth (72% cumulative FY2026-29) outpaces net income growth (50% cumulative) over the same period. 5. **Market Mispricing: Backward-Looking Multiple Applied to a Forward-Inflecting Business** At $196.39, BDX trades at roughly 33.5x trailing FY2025 EPS, a multiple more consistent with a business whose earnings are permanently impaired than one where EPS nearly doubles over four years. This disconnect likely reflects investor fatigue with Alaris-related headlines and uncertainty ahead of the November 2026 FY2027 guidance call, but it also means that as formal FY2027 guidance de-risks the remediation timeline, the multiple re-rating catalyst becomes clearer and more probable. 6. **Device-Drug Combination Pipeline Offers Optionality Beyond Base Case** BD's selective moves into device-drug combination products represent an uncontested market space play that could support premium pricing and margin mix beyond what is embedded in our base case forecast. While BD's Rule Breaker score of 4.45/10 confirms this is not a business built on disruptive innovation, the Blue Ocean score of 6.0/10 suggests pockets of differentiated value creation exist, particularly in combination products, that could provide upside optionality to the FY2028-29 numbers beyond the base case margin assumptions.

Risks

1. **Alaris Litigation and Remediation Costs Could Exceed Reserves** The $98M product liability accrual against 2,380 pending loss contingency claims may prove insufficient if settlement costs or additional claims escalate, and the remediation timeline extending into FY2027 with a 200bps revenue headwind creates execution risk if the FDA or regulatory remediation process takes longer than management currently anticipates, which would delay the margin recovery embedded in our FY2027-28 forecasts. 2. **Tariff and Input Cost Pressure Could Persist Longer Than Modeled** Our forecast assumes WTI oil prices in the 80-100 band and tariff costs that are manageable within the 25% adjusted operating margin target, but if trade policy escalates further or commodity costs spike beyond this range, the margin expansion assumed for FY2027-29 could be delayed or reduced, directly impacting the EPS trajectory that underpins our price targets. 3. **China Market Volatility Creates Revenue Uncertainty** BD's exposure to China, a market noted for volatility in the research context, creates risk to the FX-neutral revenue growth assumptions, particularly given ongoing geopolitical tensions, local procurement preferences favoring domestic medtech champions, and potential further value-based procurement pricing pressure that could compress both volume and price in this market faster than modeled. 4. **Contested Competitive Position Limits Pricing Power** With a Rule Breaker score of only 4.45/10, BD operates predominantly in mature, contested medtech categories against entrenched rivals in blood collection, infusion, and vascular intervention. This limits the company's ability to drive outsized pricing gains, meaning the margin expansion thesis depends heavily on internal cost productivity (BD Excellence) rather than market power, and any slippage in execution of these productivity programs would directly compress the EPS growth path. 5. **FY2027 Guidance Uncertainty Ahead of November Call** Management has only provided preliminary, qualitative FY2027 commentary ('modest EPS leverage,' low single-digit revenue growth) without formal guidance, creating a near-term catalyst risk: if the November 2026 earnings call delivers guidance below the modest leverage framing, particularly if Alaris headwind phasing proves worse than the flagged 200bps, the stock could de-rate further before any recovery narrative takes hold. 6. **Leverage and Capital Allocation Flexibility Constraints** Net debt held flat around $18.3-18.4B throughout the forecast period while FCF grows from $2.9B to $3.5B implies the company is prioritizing buybacks and tuck-in M&A over deleveraging; in a rising rate environment or if FCF generation disappoints relative to the 90% conversion target, this capital allocation posture could prove less flexible than assumed, constraining the per-share EPS acceleration that is central to the bull case.

📈 Price Targets